NASDAQ: MIRM - Mirum Pharmaceuticals, Inc.

Rentabilidade por seis meses: +19.12%
Rendimento de dividendos: 0.00%
Setor: Healthcare

Cronograma de promoção Mirum Pharmaceuticals, Inc.

Agenda avançada Gráfico simples
Financial Markets by TradingView

Sobre a empresa Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals, Inc., биофармацевтическая компания, занимается разработкой и коммерциализацией новых методов лечения изнурительных редких и орфанных заболеваний. Ведущим продуктом компании является ЛИВМАРЛИ, исследуемый пероральный препарат для лечения прогрессирующего семейного внутрипеченочного холестаза, а также для лечения синдрома Алажиля и атрезии желчевыводящих путей. Также разрабатывается препарат Воликсибат для лечения первичного склерозирующего холангита и первичного билиарного холангита у взрослых. Компания Mirum Pharmaceuticals, Inc.

mais detalhes
была зарегистрирована в 2018 году и имеет штаб-квартиру в Фостер-Сити, штат Калифорния.
Adicionar à lista de comparação
Adicionar à lista de observação
Adicionar ao portfólio
Adicionar aviso de preço

IPO date 2019-07-18
ISIN US6047491013
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.mirumpharma.com
Цена ао 46.28
Alteração de preço por dia: 0% (46.28)
Alteração de preço por semana: -3.32% (47.87)
Alteração de preço por mês: -7.31% (49.93)
Alteração de preço em 3 meses: +10.11% (42.03)
Mudança de preço em seis meses: +19.12% (38.85)
Mudança de preço por ano: +84.24% (25.12)
Mudança de preço em 3 anos: +101.04% (23.02)
Mudança de preço em 5 anos: +182.02% (16.41)
Mudança de preço desde o início do ano: +11.92% (41.35)
Todos os parâmetros

Subestimação

Nome Significado Nota
P/S 6.64 1
P/BV 4.97 3
P/E 0 0
EV/EBITDA -12.8 0
Total: 3.75

Eficiência

Nome Significado Nota
ROA, % -25.27 0
ROE, % -65.72 0
Total: 0

Dividendos

Nome Significado Nota
Div yield, % 0 0
DSI 0 0
Total: 0

Obrigação

Nome Significado Nota
Debt/EBITDA -3.13 10
Total: 8

Impulso de crescimento

Nome Significado Nota
Rentabilidade Revenue, % 1594.31 10
Rentabilidade Ebitda, % 149.33 10
Rentabilidade EPS, % -12.64 0
Total: 8
Mais detalhes

ETFCompartilhar, %Rentabilidade para o ano, %Dividendos, %
Innovator IBD 50 ETF 3.02537 31.06 0.08939
Virtus LifeSci Biotech Products ETF 2.13686 36.79 0.13953
First Trust Small Cap Growth AlphaDEX Fund 0.64532 42.5 1.22182
First Trust Innovation Leaders ETF 0.62442 45.14 0.51521
iShares Micro-Cap ETF 0.3876 17.09 1.54048
First Trust Small Cap Core AlphaDEX Fund 0.32871 17.31 1.87983
iShares MSCI USA Small-Cap Min Vol Factor ETF 0.25378 18.2 1.66828
Direxion Daily S&P Biotech Bull 3x Shares 0.21991 4067.92 0.25924
Future Tech ETF 0.1795 426.34 0.8416
Principal Healthcare Innovators ETF 0.1795 618.5 0.8416
Invesco Nasdaq Biotechnology ETF 0.17848 28.58 0.8565
First Trust Multi Cap Growth AlphaDEX Fund 0.13656 41.56 1.02425
Vanguard Russell 2000 Growth ETF 0.13 23.05 0.60264
ProShares Ultra Nasdaq Biotechnology 0.11877 51.7 0.85651
iShares Russell 2000 Growth ETF 0.11267 38.04 0.6026
Vanguard Russell 2000 ETF 0.06 17.16 1.48801
iShares Morningstar Small-Cap Growth ETF 0.05575 33.63 0.72598
iShares Morningstar Small-Cap Growth ETF 0.05575 587.89 0.72598
Schwab U.S. Small-Cap ETF 0.04093 17.47 1.51433
ProShares UltraPro Russell2000 0.033 89.82 1.47873
iShares Morningstar Small-Cap ETF 0.02842 30.1 1.60498
iShares Morningstar Small-Cap ETF 0.02842 391.25 1.60498
Fidelity MSCI Health Care Index ETF 0.02157 3 1.46057
ProShares Hedge Replication ETF 0.00911 5.92 1.47892
Humankind US Stock ETF 0.00517 18.81 1.99919
Schwab U.S. Broad Market ETF 0.00302 24.86 1.43354
iShares Russell 3000 ETF 0.00274 24.83 1.43482
Dimensional US Core Equity Market ETF 0.00031 30.98 1.40618
Vanguard Russell 3000 ETF 0 31.87 1.43817
0.31234.871.13



Supervisor Cargo Pagamento Ano de nascimento
Mr. Christopher Peetz CEO & Director 1.09M 1979 (46 anos)
Mr. Peter Radovich M.B.A., Ph.D. COO & President 732.15k 1978 (47 anos)
Dr. Pamela Vig Ph.D. Chief Scientific Officer 678.2k 1971 (54 ano)
Ms. Lara Longpre MBA, MSC Chief Development Officer 678.2k 1970 (55 anos)
Andrew McKibben Vice President of Investor Relations and Finance N/A
Mr. Paul K. Ross Chief Compliance Officer N/A
Ms. Erin Campany Senior Vice President of Human Resources N/A 1968 (57 anos)
Ms. Vinita P. Kumar Senior vice President of Quality N/A
Mr. Eric H. Bjerkholt M.B.A. Chief Financial Officer N/A 1960 (65 anos)
Dr. Jean-Luc Girardet Ph.D. Senior Vice President of Technical Operations

Endereço: United States, Foster City. CA, 950 Tower Lane - abrir no Google Maps, abrir mapas Yandex
Site: https://www.mirumpharma.com